KIR3DL2 is expressed irrespectively of disease stage in all subtypes of CTCL, with the highest prevalence in SS and transformed MF, two subsets with high and unmet therapeutic needs. Here, KIR3DL2 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.